Skip to main content

Table 1 The association between BRAF V600 mutation status and clinicopathologic characteristics

From: BRAF V600 mutation profiling in primary skin nodular melanoma in Indonesia: an analysis using high resolution pyrosequencing

 

BRAF (+)

BRAF (−)

p value**

Age, mean ± SD*

60.67 ± 15.81

60.67 ± 13.49

1.000

Age category, n (%)

 < 65 years

13 (33.33)

10 (25.64)

0.469

 ≥ 65 years

8 (20.51)

8 (20.51)

 

Sex, n (%)

 Male

8 (20.51)

9 (23.08)

0.336

 Female

13 (33.33)

9 (23.08)

 

Anatomic location, n (%)

 Extremity

14 (35.90)

15 (38.46)

0.207

 Central

7 (17.95)

3 (7.69)

 

Lymph node metastasis, n (%)

 Present

10 (25.64)

8 (20.51)

0.549

 Absent

11 (28.21)

10 (25.64)

 

Tumor thickness, n (%)

 ≤ 4 mm

1 (2.56)

3 (7.69)

0.246

 > 4 mm

20 (51.28)

15 (38.46)

 

Ulceration, n (%)

 Present

10 (25.64)

12 (30.77)

0.192

 Absent

11 (28.21)

6 (15.38)

 

Mitotic index, mean ± SD*

25.82 ± 18.77

23.22 ± 16.08

0.648

Mitotic index category, n (%)

 ≥ 20%

12 (30.77)

10 (25.64)

0.588

 < 20%

9 (23.08)

8 (20.51)

 

Necrosis, n (%)

 Present

17 (43.59)

11 (28.21)

0.570

 Absent

4 (10.26)

7 (17.95)

 

Lymphovascular invasion, n (%)

 Present

9 (23.08)

4 (10.26)

0.153

 Absent

12 (30.77)

14 (35.90)

 

Tumor-infiltrating lymphocytes, n (%)

 Present

13 (33.33)

13 (33.33)

0.368

 Absent

8 (20.51)

5 (12.82)

 
  1. *SD standard deviation
  2. **p value < 0.05 was considered significant